These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 18309487)

  • 21. TNFRII polymorphism is associated with response to TNF blockers in rheumatoid arthritis patients seronegative for ACPA.
    Pers YM; Cadart D; Rittore C; Ravel P; Daïen V; Fabre S; Jorgensen C; Touitou I
    Joint Bone Spine; 2014 Jul; 81(4):370-2. PubMed ID: 24462126
    [No Abstract]   [Full Text] [Related]  

  • 22. Genetic variants within the TNFRSF1B gene and susceptibility to rheumatoid arthritis and response to anti-TNF drugs: a multicenter study.
    Canet LM; Filipescu I; Cáliz R; Lupiañez CB; Canhão H; Escudero A; Segura-Catena J; Soto-Pino MJ; Ferrer MA; García A; Romani L; Pérez-Pampin E; González-Utrilla A; López Nevot MA; Collantes E; Fonseca JE; Sainz J
    Pharmacogenet Genomics; 2015 Jul; 25(7):323-33. PubMed ID: 25850964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of tumor necrosis factor (TNF)-alpha and TNF receptor polymorphisms in susceptibility to ankylosing spondylitis.
    Chatzikyriakidou A; Georgiou I; Voulgari PV; Drosos AA
    Clin Exp Rheumatol; 2009; 27(4):645-8. PubMed ID: 19772798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
    Cañete JD; Suárez B; Hernández MV; Sanmartí R; Rego I; Celis R; Moll C; Pinto JA; Blanco FJ; Lozano F
    Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Associations between PTPRC rs10919563 A/G and FCGR2A R131H polymorphisms and responsiveness to TNF blockers in rheumatoid arthritis: a meta-analysis.
    Lee YH; Bae SC
    Rheumatol Int; 2016 Jun; 36(6):837-44. PubMed ID: 27074847
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
    Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNFalpha blocking agents in rheumatoid arthritis.
    Benucci M; Saviola G; Baiardi P; Cammelli E; Manfredi M
    Clin Rheumatol; 2008 Jan; 27(1):91-5. PubMed ID: 17929076
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contribution of PTPN22 1858T, TNFRII 196R and HLA-shared epitope alleles with rheumatoid factor and anti-citrullinated protein antibodies to very early rheumatoid arthritis diagnosis.
    Goëb V; Dieudé P; Daveau R; Thomas-L'otellier M; Jouen F; Hau F; Boumier P; Tron F; Gilbert D; Fardellone P; Cornélis F; Le Loët X; Vittecoq O
    Rheumatology (Oxford); 2008 Aug; 47(8):1208-12. PubMed ID: 18535030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IgA rheumatoid factor as a serological predictor of poor response to tumour necrosis factor α inhibitors in rheumatoid arthritis.
    Sakthiswary R; Shaharir SS; Mohd Said MS; Asrul AW; Shahril NS
    Int J Rheum Dis; 2014 Nov; 17(8):872-7. PubMed ID: 25292482
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TNFα antagonist therapy does not increase the Epstein-Barr virus burden in patients with rheumatoid arthritis or ankylosing spondylitis.
    Couderc M; Payet S; Henquell C; Dubost JJ; Soubrier M
    Joint Bone Spine; 2010 Oct; 77(5):414-7. PubMed ID: 20542718
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor necrosis factor alpha 5'-flanking region, tumor necrosis factor receptor II, and HLA-DRB1 polymorphisms in Japanese patients with rheumatoid arthritis.
    Shibue T; Tsuchiya N; Komata T; Matsushita M; Shiota M; Ohashi J; Wakui M; Matsuta K; Tokunaga K
    Arthritis Rheum; 2000 Apr; 43(4):753-7. PubMed ID: 10765919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor necrosis factor-alpha receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritis.
    Fabris M; Tolusso B; Di Poi E; Assaloni R; Sinigaglia L; Ferraccioli G
    J Rheumatol; 2002 Sep; 29(9):1847-50. PubMed ID: 12233877
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis.
    Maxwell JR; Potter C; Hyrich KL; ; Barton A; Worthington J; Isaacs JD; Morgan AW; Wilson AG
    Hum Mol Genet; 2008 Nov; 17(22):3532-8. PubMed ID: 18713756
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways.
    Potter C; Cordell HJ; Barton A; Daly AK; Hyrich KL; Mann DA; Morgan AW; Wilson AG; ; Isaacs JD
    Ann Rheum Dis; 2010 Jul; 69(7):1315-20. PubMed ID: 20448286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor necrosis factor alpha-308 and -238 polymorphisms in rheumatoid arthritis. Association with messenger RNA expression and sTNF-alpha.
    Oregón-Romero E; Vázquez-Del Mercado M; Ruiz-Quezada SL; Navarro-Hernández RE; Rangel-Villalobos H; Martínez-Bonilla G; Bernard-Medina AG; Armendáriz-Borunda J; García-Bañuelos J; Muñoz-Valle JF
    J Investig Med; 2008 Oct; 56(7):937-43. PubMed ID: 18797411
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reasons for Discontinuation and Adverse Effects of TNFα Inhibitors in a Cohort of Patients With Rheumatoid Arthritis and Ankylosing Spondylitis.
    García-Lagunar MH; Gutiérrez-Cívicos MR; García-Simón MS; Conesa-Zamora P; Jimenez-Santos E; Cano-Vivar P; García-Márquez A; Muñoz-García I; Viney AC
    Ann Pharmacother; 2017 May; 51(5):388-393. PubMed ID: 27920336
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biomarkers for prediction of TNFalpha blockers response in rheumatoid arthritis.
    Marotte H; Miossec P
    Joint Bone Spine; 2010 Jul; 77(4):297-305. PubMed ID: 20478724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lack of association of tumor necrosis factor alpha gene polymorphism in patients with rheumatoid arthritis in central Taiwan.
    Lo SF; Huang CM; Wu MC; Wu JY; Tsai FJ
    Rheumatol Int; 2003 Jul; 23(4):151-3. PubMed ID: 12750939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists.
    Curtis JR; Patkar N; Xie A; Martin C; Allison JJ; Saag M; Shatin D; Saag KG
    Arthritis Rheum; 2007 Apr; 56(4):1125-33. PubMed ID: 17393394
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of polymorphisms of HLA-DRB1 and TNF-308 G/A with radiographic joint damage in patients with early rheumatoid arthritis with high inflammatory activity, treated according to the principle of "Treat to target" (REMARKA study).
    Guseva IA; Smirnov AV; Demidova NV; Krylov MY; Avdeeva AS; Samarkina EY; Luchikhina EL; Karateev DE; Abramov DD; Nasonov EL
    Ter Arkh; 2018 May; 90(5):38-43. PubMed ID: 30701887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.